secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2026-03-04T23:59:59+00:00
Accession:  0001104659-26-023169
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar Biosciences reports FY2025 net loss $21.8M, cash $13.2M; plans EMA submission Q3 2026
--------------------------------------------------------------------------------

- Net loss $21.8M ($8.35/share) vs $44.6M ($36.52/share) in 2024; company pre-revenue.
- Cash $13.2M at Dec 31, 2025, expected to fund operations into Q3 2026.
- Plans to submit Conditional Marketing Authorization for iopofosine I 131 to EMA in Q3 2026.
- Initiated Phase 1b study of CLR 125 in triple negative breast cancer; early data mid-2026.
- Received FDA Breakthrough Therapy Designation for iopofosine I 131 in relapsed/refractory WM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465926023169/0001104659-26-023169-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465926023169/tm267955d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-023169

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer